prikaz prve stranice dokumenta Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society
  Download
PDF 272.83 KB
Scientific paper - Review paper
Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society
Croatian Medical Journal, 63 (2022), 4; 379-388. https://doi.org/10.3325/cmj.2022.63.379
Habek, Mario; Adamec, Ivan; Barun, Barbara; Bašić Kes, Vanja; Bogoje Raspopović, Andrijana; Duka Glavor, Klaudia; Gabelić, Tereza; Grzinčić, Tihana; Jukić, Mirjam; Jurašić, Miljenka-Jelena; Kiđemet-Piskač, Spomenka; Komšo, Milica; Rimac, Julija; Lazibat, Ines; Lukić, Branka; Marčinko, Anita; Matijaca, Meri; Ratković, Marija; Šapina, Lidija; Vuletić, Vladimira; Mirošević Zubonja, Tea; Krbot Skorić, Magdalena More authors...

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Habek, M., Adamec, I., Barun, B., Bašić Kes, V., Bogoje Raspopović, A., Duka Glavor, K. ... Krbot Skorić, M. (2022). Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society. Croatian Medical Journal, 63. (4), 379-388. doi: 10.3325/cmj.2022.63.379

Habek, Mario, et al. "Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society." Croatian Medical Journal, vol. 63, no. 4, 2022, pp. 379-388. https://doi.org/10.3325/cmj.2022.63.379

Habek, Mario, Ivan Adamec, Barbara Barun, Vanja Bašić Kes, Andrijana Bogoje Raspopović, Klaudia Duka Glavor, Tereza Gabelić, et al. "Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society." Croatian Medical Journal 63, no. 4 (2022): 379-388. https://doi.org/10.3325/cmj.2022.63.379

Habek, M., et al. (2022) 'Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society', Croatian Medical Journal, 63(4), pp. 379-388. doi: 10.3325/cmj.2022.63.379

Habek M, Adamec I, Barun B, Bašić Kes V, Bogoje Raspopović A, Duka Glavor K, and sur.. Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society. Croatian Medical Journal [Internet]. 2022 August 31 [cited 2024 December 27];63(4):379-388. doi: 10.3325/cmj.2022.63.379

M. Habek, et al., "Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society", Croatian Medical Journal, vol. 63, no. 4, pp. 379-388, August 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:930884. [Accessed: 27 December 2024]

Metadata
Title (english)Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society
AuthorMario Habek
AuthorIvan Adamec
AuthorBarbara Barun
AuthorVanja Bašić Kes
AuthorAndrijana Bogoje Raspopović
AuthorKlaudia Duka Glavor
AuthorTereza Gabelić
AuthorTihana Grzinčić
AuthorMirjam Jukić
AuthorMiljenka-Jelena Jurašić
AuthorSpomenka Kiđemet-Piskač
AuthorMilica Komšo
AuthorJulija Rimac
AuthorInes Lazibat
AuthorBranka Lukić
AuthorAnita Marčinko
AuthorMeri Matijaca
AuthorMarija Ratković
AuthorLidija Šapina
AuthorVladimira Vuletić
AuthorTea Mirošević Zubonja
AuthorMagdalena Krbot Skorić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Neurology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Untreated multiple sclerosis (MS) irretrievably leads to severe neurological impairment. In European health care systems, patient access to disease modifying therapies (DMT) is often confined to more advanced stages of the disease because of restrictions in reimbursement. A discrepancy in access to DMTs is evident between West and East European countries. In order to improve access to DMTs for people with MS (pwMS) living in Croatia, the Croatian Neurological Society issued new recommendations for the treatment of relapsing MS. The aim of this article is to present these recommendations. The recommendations for platform therapies are to start DMT as soon as the diagnosis is made. If poor prognostic criteria are present (≥9 T2 or FLAIR lesions on the initial brain and spinal cord magnetic resonance imaging [MRI] or ≥3 T1 lesions with postcontrast enhancement on the initial brain and spinal cord MRI or Expanded Disability Status Scale after treatment of the initial relapse ≥3), high-efficacy DMT should be initiated. If pwMS experience ≥1 relapse or ≥3 new T2 lesions while on platform therapies, they should be switched to high-efficacy DMT. Further efforts should be made to enable early and unrestricted access to high-efficacy DMT with a freedom of choice of an appropriate therapy for expert physicians and pwMS. The improvement of access to DMT achieved by the implementation of national treatment guidelines in Croatia can serve as an example to national neurological societies from other Eastern European countries to persuade payers to enable early and unrestricted treatment of pwMS.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCroatian Medical Journal
Numberingvol. 63, no. 4, pp. 379-388
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2022.63.379
URN:NBNurn:nbn:hr:105:930884
Publication2022-08-31
Document URLhttp://www.cmj.hr/2022/63/4/36046935.htm
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2022-09-26 08:02:21